Art. -Nr.: HY-11038D

Zelavespib formic

Name: Zelavespib formic
Brand: MedChemExpress
SKU: HY-11038D
Price: 69.00 USD
Availability: InStock
Rating: 5 (13 reviews)

(Synonyms: PU-H71 formic)

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC₅₀ value of 51 nM for Hsp90 in MDA-MB-468 cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 97.39%
Formel: C₁₉H₂₃IN₆O₄S
Molecular Weight:558.39

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Zelavespib formic Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC₅₀ value of 51 nM for Hsp90 in MDA-MB-468 cells^[1].

IC₅₀ & Target^[1]

HSP90

51 nM (IC₅₀)

Alle HSP Isoform-spezifische Produkte anzeigen :

Chemical Information

Appearance Solid
Molecular Weight 558.39
Formel C₁₉H₂₃IN₆O₄S
Color White to off-white
SMILES

CC(C)NCCCN1C(SC2=C(C=C3OCOC3=C2)I)=NC4=C(N=CN=C14)N.OC=O
Synonyms

PU-H71 formic
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (13)

All WBRT-PCRCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286

Zelavespib formic purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]

Inoculation of THP-1 cells into 12-well cell culture plates and treated with indicated doses of Pimitespib, IPI-504, PU-H71 (0, 15, 30, 62.5, 125, 250, 500, 1000 nM), or STA-9090 for 18 h. SAMHD1 protein levels were analyzed by western blot.

Zelavespib formic purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]

RT-qPCR analysis of SAMHD1 mRNA levels in THP-1 cells treated with indicated concentrations of HSP90 inhibitors (IPI-504 (125, 250, 500 nM), PU-H71, or STA-9090) for 18 h.

Zelavespib formic purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]

MTT assay measuring THP-1 cell viability after 18-hour treatment with PU-H71 (0, 125, 250, 500 nM).
Nat Commun

Identification of HSP90 inhibitors as a novel class of senolytics. [Abstract]

2017 Sep 4;8(1):422. PMID: 28871086
Theranostics

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System. [Abstract]

2019 Aug 12;9(20):5769-5783. PMID: 31534518
Theranostics

Evaluation of [11C]NMS-E973 as a PET tracer for in vivo visualisation of HSP90. [Abstract]

2019 Jan 1;9(2):554-572. PMID: 30809293
J Control Release

The HSP90-dependent bioorthogonal PROTAC prodrug system enables tumor-selective and enhanced protein degradation. [Abstract]

2026 May 10:393:114828. PMID: 41839264
Pharmacol Res

Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. [Abstract]

2020 Jan:151:104512. PMID: 31726100
Int J Biol Macromol

17-AAG promotes the degradation of HSP90 client METTL3 to suppress MYC RNA m6A modification and expression in colorectal cancer. [Abstract]

2025 Dec 3;337(Pt 1):149421. PMID: 41349747
Br J Pharmacol

Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice. [Abstract]

2021 Nov;178(22):4485-4500. PMID: 34265073
Curr Issues Mol Biol

FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. [Abstract]

2024 Mar 29;46(4):2946-2960. PMID: 38666914
Curr Issues Mol Biol

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. [Abstract]

2023 Aug 23;45(9):7011-7026. PMID: 37754227
Viruses

Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. [Abstract]

2021 Apr 2;13(4):610. PMID: 33918368
Authorea

April 10, 2021.
bioRxiv

2021 Jan 27.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (179.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7909 mL

8.9543 mL

17.9086 mL

5 mM

0.3582 mL

1.7909 mL

3.5817 mL

10 mM

0.1791 mL

0.8954 mL

1.7909 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Caldas-Lopes E, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7909 mL	8.9543 mL	17.9086 mL	44.7716 mL
	5 mM	0.3582 mL	1.7909 mL	3.5817 mL	8.9543 mL
	10 mM	0.1791 mL	0.8954 mL	1.7909 mL	4.4772 mL
	15 mM	0.1194 mL	0.5970 mL	1.1939 mL	2.9848 mL
	20 mM	0.0895 mL	0.4477 mL	0.8954 mL	2.2386 mL
	25 mM	0.0716 mL	0.3582 mL	0.7163 mL	1.7909 mL
	30 mM	0.0597 mL	0.2985 mL	0.5970 mL	1.4924 mL
	40 mM	0.0448 mL	0.2239 mL	0.4477 mL	1.1193 mL
	50 mM	0.0358 mL	0.1791 mL	0.3582 mL	0.8954 mL
	60 mM	0.0298 mL	0.1492 mL	0.2985 mL	0.7462 mL
	80 mM	0.0224 mL	0.1119 mL	0.2239 mL	0.5596 mL
	100 mM	0.0179 mL	0.0895 mL	0.1791 mL	0.4477 mL

Bioz

Keywords

Zelavespib formic

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Zelavespib formic

Publications Citing Use of MedChemExpress (MCE) Zelavespib formic

Alle HSP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Zelavespib formic Related Classifications

HY-11038D Related Classifications

Bioz